Skip to main content
SpringerLink
Log in

Plasma Lipidomic Alteration in Ovarian Cancer

  • Living reference work entry
  • First Online:
Encyclopedia of Lipidomics

  • 101 Accesses

Ovarian cancer (OC) is the most common cause of death from gynecologic malignancies in women of all ages in the Western world. Early stage(I/II) of OC has an excellent prognosis with a survival rate of over 90%, but approximately 80% of all reported cases were caught in the advanced stages(III/IV) with a 5-year survival rate at only 11% (Badgwell und Bast 2007; Fields und Chevlen 2006). Given the success of treatment at a early stage, a reliable diagnostic marker for OC at an early stage is intuitively attractive.

Recently, a nontargeted lipidomics approach based on ultra performance liquid chromatography-electrospray ionization-quadrupole time-of-flight-mass spectrometry (UPLC-ESI-QTOF-MS) in conjunction with multivariate data analysis, including principal component analysis (PCA) and (orthogonal) partial least squared discriminant analysis [(O)PLS-DA], was applied for the rapid investigation of lipidomic alteration in the plasma of OC patients for exploring potential diagnostic...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Badgwell Jr D, Bast RC. Early detection of ovarian cancer. Dis Markers. 2007;23:397–410.

    Google Scholar 

  • Fields MM, Chevlen E. Ovarian cancer screening: a look at the evidence. Clin J Oncol Nurs. 2006;10:77–81.

    Google Scholar 

  • Li H, Zhao ZW, Antalis C, Zhao ZZ, Emerson R, Wei G, Zhang S, Zhang ZY, Xu Y. Combination therapy of an inhibitor of group VIA phospholipase A2 with paclitaxel is highly effective in blocking ovarian cancer development. Am J Pathol. 2011;179:452–61.

    Google Scholar 

  • Li H, Zhao ZW, Wei G, Yan LB, Wang DM, Zhang H, Sandusky GE, Turk J, Xu Y. Elevated and secreted phospholipase A2 activities as new potential therapeutic targets in human epithelial ovarian cancer. FASEB J. 2012;26:3306–20.

    Google Scholar 

  • Meleh M, Pozlep B, Mlakar A, Meden-Vrtovec H, Zupancic-Kralj L. Determination of serum lysophosphatidic acid as a potential biomarker for ovarian cancer. J Chromatogr B. 2007;858:287–91.

    Google Scholar 

  • Pan SY, Ugnat AM, Mao Y, Wen SW, Johnson KC. A case-control study of diet and the risk of ovarian cancer. Cancer Epidemiol Biomark Prev. 2004;13:1521–7.

    Google Scholar 

  • Sutphen R, Xu Y, Wilbanks GD, et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomark Prev. 2004;13(7):1185–91.

    CAS  Google Scholar 

  • Tokumura A, Kume T, Fukuzawa K, et al. Peritoneal fluids from patients with certaingynecologic tumor contain elevated levels of bioactive lysophospholipase D activity. Life Sci. 2007;80(18):1641–9.

    Article  CAS  PubMed  Google Scholar 

  • Xiao YJ, Schwartz B, Washington M, Kennedy A, Webster K, Belinson J, Xu Y. Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal Biochem. 2001;290:302–13.

    Article  CAS  PubMed  Google Scholar 

  • Xu Y, Gaudette DC, Boynton JD, et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res. 1995a;1(10):1223–32.

    CAS  PubMed  Google Scholar 

  • Xu Y, Fang XJ, Casey G, Mills GB. Lysophospholipids activate ovarian and breast cancer cells. Biochem J. 1995b;309(Pt 3):933–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Xu Y, Shen ZZ, Wiper DW, Wu MZ, Morton RE, Elson P, Kennedy AW, Belinson J, Markman M, Casey G. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA. 1998;280:719–23.

    Article  CAS  PubMed  Google Scholar 

  • Xu Y, Xiao YJ, Baudhuin LM, Schwartz BM. The role and clinical applications of bioactive lysolipids in ovarian cancer. J Soc Gynecol Investig. 2001;8(1):1–13.

    Article  PubMed  Google Scholar 

  • Xu Y, Sengupta S, Singh S, Steinmetz R. Novel lipid signaling pathways in ovarian cancer cells. Cell Sci Rev. 2006;3:168–97.

    Google Scholar 

  • Zhang Y, Liu Y, Li L, Wei J, Xiong S, Zhao Z. High resolution mass spectrometry coupled with multivariate data analysis revealing plasma lipidomic alteration in ovarian cancer in Asian women. Talanta. 2016;150:88–96.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Beijing National Laboratory for Molecular Sciences, Key Laboratory of Analytical Chemistry for Living Biosystems, Institute of Chemistry Chinese Academy of Sciences, Beijing Mass Spectrum Center, Beijing, China

    Yangyang Zhang, Ming Guan, Shilei Li & Zhenwen Zhao

  2. Graduate School, University of Chinese Academy of Sciences, Beijing, China

    Ming Guan, Shilei Li & Zhenwen Zhao

Authors
  1. Yangyang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ming Guan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shilei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhenwen Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhenwen Zhao .

Editor information

Editors and Affiliations

  1. Yong Loo Lin School of Medicine Centre for Life Sciences, Singapore, Singapore

    Markus R. Wenk

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Science+Business Media B.V.

About this entry

Cite this entry

Zhang, Y., Guan, M., Li, S., Zhao, Z. (2018). Plasma Lipidomic Alteration in Ovarian Cancer. In: Wenk, M. (eds) Encyclopedia of Lipidomics. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-7864-1_172-1

Download citation

  • DOI: https://doi.org/10.1007/978-94-007-7864-1_172-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-007-7864-1

  • Online ISBN: 978-94-007-7864-1

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation